Invion Limited
IVX.ASXHealth Care
Clinical-stage pharmaceutical drug development
Market Data
$0.044
-0.1%$4.7M
-100000.0x
$-0.132
0.00%
-0.6%
Latest Earnings
Appendix 4D and Half Year Financial Report
27 February 2026
Invion Limited (ASX: IVX) reported a significant widening of its net loss to $3.57M for HY1 FY26 (ended 31 December 2025), up 90.5% from $1.87M in the prior corresponding period, driven by higher administration costs, increased R&D spending, and a near-doubling of depreciation/amortisation charges. The company achieved several clinical and strategic milestones including FDA Orphan Drug Designation for INV043 in anal cancer, an expanded global Photosoft licence, and a South Korean government-backed funding arrangement with Hanlim Pharm worth up to $2M. However, cash reserves fell sharply to just $137,543 at period end, and the auditor has flagged a material uncertainty regarding going concern. Key points: FDA Orphan Drug Designation granted for INV043 in anal cancer treatment, providing 7-year US market exclusivity post-approval, potential tax credits, and regulatory fee waivers; Expanded perpetual and exclusive global Photosoft licence secured in December 2025 (subject to shareholder approval), significantly broadening commercialisation rights; Non-dilutive South Korean KDDF government grant arrangement with Hanlim Pharm providing up to $2M for oesophageal cancer preclinical studies and clinical trial preparation
Recent Announcements
Appendix 4D and Half Year Financial Report
Invion Limited (ASX: IVX) reported a significant widening of its net loss to $3.57M for HY1 FY26 (ended 31 December 2025), up 90.5% from $1.87M in the prior corresponding period, driven by higher administration costs, increased R&D spending, and a near-doubling of depreciation/amortisation charges. The company achieved several clinical and strategic milestones including FDA Orphan Drug Designation for INV043 in anal cancer, an expanded global Photosoft licence, and a South Korean government-backed funding arrangement with Hanlim Pharm worth up to $2M. However, cash reserves fell sharply to just $137,543 at period end, and the auditor has flagged a material uncertainty regarding going concern. Key points: FDA Orphan Drug Designation granted for INV043 in anal cancer treatment, providing 7-year US market exclusivity post-approval, potential tax credits, and regulatory fee waivers; Expanded perpetual and exclusive global Photosoft licence secured in December 2025 (subject to shareholder approval), significantly broadening commercialisation rights; Non-dilutive South Korean KDDF government grant arrangement with Hanlim Pharm providing up to $2M for oesophageal cancer preclinical studies and clinical trial preparation
Get real-time alerts for IVX
Receive AI-powered earnings summaries and instant notifications when Invion Limited releases results.
Register Free